White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
Bank Regulation Rollbacks in the U.S. and UK Could Increase Financial Risks, Study Warns 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
